Growth Metrics

Lexaria Bioscience (LEXX) Change in Account Payables (2016 - 2021)

Lexaria Bioscience's Change in Account Payables history spans 7 years, with the latest figure at -$5223.0 for Q4 2021.

  • Quarterly results put Change in Account Payables at -$5223.0 for Q4 2021, down 118.34% from a year ago — trailing twelve months through Aug 2022 was -$5223.0 (up 90.23% YoY), and the annual figure for FY2022 was -$5223.0, up 90.23%.
  • Change in Account Payables for Q4 2021 was -$5223.0 at Lexaria Bioscience, down from $3899.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $119621.0 in Q1 2021 to a low of -$243169.0 in Q2 2017.
  • The 5-year median for Change in Account Payables is $1130.5 (2018), against an average of -$16399.6.
  • The sharpest move saw Change in Account Payables crashed 2857.33% in 2017, then soared 2259.44% in 2019.
  • Year by year, Change in Account Payables stood at -$17672.0 in 2017, then soared by 178.08% to $13799.0 in 2018, then tumbled by 178.96% to -$10896.0 in 2019, then skyrocketed by 361.39% to $28481.0 in 2020, then tumbled by 118.34% to -$5223.0 in 2021.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$5223.0, $3899.0, and -$205482.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.